PRR11 and breast carcinoma: Furthermore, breast cancer cell lines with PRR11 amplification displayed significantly higher sensitivity to the PI3K inhibitor pictilisib compared to cell lines without PRR11 amplification in the LINCS MGH/Sanger dataset of Drug/Cell-line Browser (DCB42; Fig. 7c).